

**Supplementary Table 1 Clinical and pathological characteristics of the entire cohort**

<b>Parameters</b>	<b><i>n</i></b>	<b>%</b>
Mean age (63.8 yr); range [40-81]	159	100
Sex		
Male	93	58
Female	66	42
Histological grade		
G1 + G2	88	55
G3 + G4	67	42
Not reported	4	3
Localization		
Head	141	89
Tail	18	11
Primary tumor (pT)		
pT1	20	13
pT2	34	21
pT3	102	64
pT4	3	2
Regional lymph nodes (pN)		
pN0	74	47
pN1	85	53
Microangioinvasion (pAI)		
pAI0	119	75
pAI1	29	18
Not reported	11	7
Perineural Invasion (pPN)		
pPN0	42	26
pPN1	106	67
Not reported	11	7
Lymphovascular invasion (pLI)		

pLI0	96	60
pLI1	52	33
Not reported	11	7
Neoadjuvant therapy		
Yes	2	1
No	157	99
Adjuvant therapy		
Yes	111	70
No	43	27
No information	5	3
Status at follow-up		
Alive	25	16
Deceased	134	84

**Supplementary Table 2 Clinical and pathological characteristics in patients with metachronous metastases**

Parameters	Non-pulmonary	Pulmonary	<i>P</i> value	Isolated pulmonary	Isolated-oligo	Isolated-multiple	Pulmonary and others
Mean age	63.9	61.3	0.214	54.4	57	50.5	63.6
Sex			<b>0.012</b>				
Male	59	6		0	0	0	6
Female	38	14		5	3	2	9
Histological grade			0.636				
G1 + G2	47	10		2	1	1	8
G3 + G4	48	8		2	2	0	6
Not reported	2	2		1	0	1	1
Localization			0.339				
Head	85	19		5	3	2	14
Tail	12	1		0	0	0	1
Primary tumor (pT)			0.263				
pT1	10	4		2	1	1	2
pT2	21	2		0	0	0	2
pT3	65	13		3	2	1	10
pT4	1	1		0	0	0	1
Regional lymph node (pN)			0.308				
pN0	41	6		3	2	1	3
pN1	56	14		2	1	1	12
Microangioinvasion (AI)			0.751				
pAI0	69	15		4	2	2	11
pAI1	23	4		1	1	0	3
Not reported	5	1		0	0	0	1
Perineural invasion (PI)			0.057				
pPI0	23	1		0	0	0	1

pPI1	69	18		5	3	2	13
Lymphovascular invasion (LI)			0.879				
pLI0	55	11		4	3	1	7
pLI1	37	8		1	0	1	7
Not reported	5	1		0	0	0	1
Neoadjuvant therapy							
Yes	1	1		1	0	1	0
No	96	19		4	3	2	15
Adjuvant therapy			0.294				
Yes	71	17		4	2	2	13
No	25	3		1	1	0	2
No information	1	0		0	0	0	0
Status at follow-up			0.004				
Alive	3	4		2	2	0	2
Deceased	94	16		3	1	2	13

Supplementary Table 3 Demographics, stage, tumor characteristics, therapy, disease free survival and overall survival of individual patients with pulmonary metastases

Sex	Age	Stage	Grade	CHTI	RTI	DFS	RLi	RLo	RLN	RPu	RPe	RPa	Surg	CHTII	RTII	TTD	AdM	OS
F	44	I	nr	GEM		22				yM			Th,B	FU+Opl		60	Br	82.5
F	57	IIB	2	FuFa+Xel	y	38				yM				GEM		12.5		50.5
F	48	IIB	2	NS		13				yO				GEM		12.5	Li	26.5
F	57	IIA	3	GEM	y	52				yO			Res	GEM				63+
F	66	I	3	GEM		34				yO			Res	D				47+
F	55	IIA	2	FUFA	y	26	y		PA	y				GEM		3.5		30.5
F	61	IIB	3	GEM		49			PA	y				GEM		6.5		56
M	53	IV	1	GEM		17	y			y				GEM		15.5		33.5
F	61	III	3	GEM		5	y			y				n		5		10
F	60	IIA	2	GEM		8				y	y			n		0.5		8.5
F	66	IIB	3	GEM		7	y		RP	y				n		2		9
M	75	IIB	nr	GEM		10			MED	y		y		n		5.5		15.5
M	77	IIB	3	GEM		9		y		y+Pl				n		3		12
M	64	IIB	3	GEM		31			PA	y				n		14		45
F	56	IIB	1	GEM		58				y		y		FOLFIRIN OX→GEM				73+
M	63	I	1	NI		47				y		y		n		5		52
F	47	IIB	3	GEM		17	y	y		y				5FU	y	6		23
F	67	IIB	2	GEM		23				y	y			FUFA		11		34
M	72	IIB	2	5FU		6				y +Pl				n		1.5		7.5
F	77	IIB	2	D		35			PA	y				n				44.5+

CHTI: 1<sup>st</sup> line chemotherapy; RTI: 1<sup>st</sup> line radiotherapy; DFS: Disease free survival; RLi: Liver recurrence; RLo: Local recurrence; RLN: Lymph node recurrence, RPu: Pulmonary recurrence; RPe: Peritoneal recurrence; RPa: Pancreatic recurrence; Surg: Surgery; Th: Thoracoscopy; B: Biopsy; Res: Resection; CHTII: 2<sup>nd</sup> line chemotherapy; RTII: Second line radiotherapy; TTD: Time to death; AdM: Additional metastasis; OS: Overall survival; y: Yes; n: No; nr: Not reported; yM: Yes multiple; yO: Yes oligometastatic; GEM: Gemcitabine; FuFa: Combination of 5-fluorouracil and folinic acid; Xel: Capecitabine; Pl: Pleura, D: Denied; NS: Not started; Br: Brain; Li: Liver; NI: Not indicated; PA: Paraaortal; MED: Mediastinal; FOLFIRINOX: Combination of oxaliplatin, irinotecan, 5-fluorouracil and folinic acid.